SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on August 7, 2020, covering events occurring on August 5 and August 6, 2020. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The report discloses the following material corporate developments regarding ViralClear Pharmaceuticals, Inc., the Company's majority-owned subsidiary:
- August 5, 2020: Dr. Michael J. Sofia joined the Scientific Advisory Board (SAB) of ViralClear.
- August 6, 2020: Professor Angus Dalgleish joined the SAB of ViralClear.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the attached press releases. The filing includes a standard disclaimer that the information provided under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination that the information is material or required by Regulation FD. No financial guidance or specific risk factors were disclosed in this document.
Investor Verification Checklist
- Verify the full text of the press releases attached as Exhibits 99.1 and 99.2 for details on the new advisory board members' backgrounds.
- Confirm the current ownership percentage of ViralClear Pharmaceuticals, Inc. held by BioSig Technologies, Inc.
- Review recent 10-Q or 10-K filings for the most up-to-date financial position, as this 8-K contains no financial data.